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In this era of some pharmaceutical com-
panies being accused of behaving poorly
over the past two decades by hiding safety
signals to maintain profits, it is refreshing
to reflect back on a very different expe-
rience as an employe of Lederle Labora-
tories (now Pfizer). When in 1991 this
company was informed by an investiga-
tor about a safety issue with piperacillin
(Pipracil®), the response was adequate as I
will demonstrate below.
I began my industry career in phase IV
anti-infectives. We designed studies lead-
ing to new indications and tracked the
safety of our products. I monitored all tri-
als with three different antibiotics. One of
my trials enrolled patients who had pene-
trating abdominal trauma (due to a knife
wound or gunshot). We selected trauma
surgeons as investigators who worked in
large University trauma centers (“knife and
gun clubs”). We expected cases with colonic
penetration resulting in spillage of gut
bacteria into the abdomen to benefit of
piperacillin versus a comparator antibiotic.
Perioperatively, patients received one of the
two study antibiotics plus vecuronium, a
non-depolarizing neuromuscular blocking
agent. An investigator informed me of the
adverse event of prolonged neuromuscular
blockade after an abdominal operation.
The investigator knew the Drug Inter-
action section in vecuronium’s package
insert (1) included a statement that par-
enteral/intraperitoneal administration of
high doses of certain antibiotics may inten-
sify or produce neuromuscular block-
ade on their own. Penicillins, including
piperacillin were not listed. If these or
other newly introduced antibiotics are
used in conjunction with vecuronium,
unexpected prolongation of neuromuscu-
lar block should be considered a possibility.
So, the investigator wanted to break the
blind to determine if this subject received
piperacillin.
My medical director asked a colleague
uninvolved with this trial to break the
blind. We discovered the patient received
our drug. Vecuronium’s package insert
(Adverse Reactions section) states the
most frequent adverse reaction to non-
depolarizing blocking agents as a class
consists of an extension of the drug’s
pharmacological action beyond the time
period needed. This may vary from skele-
tal muscle weakness to profound and pro-
longed skeletal muscle paralysis resulting
in respiration insufficiency or apnea. What
should my company do with the knowl-
edge of this adverse event reported from
one of its clinical trials? Lederle, a very
ethical big pharmaceutical company did
the right thing. We designed and con-
ducted a small study (30 subjects) to
determine the magnitude of the neuro-
muscular blockade of piperacillin in com-
bination with vecuronium. We included
a positive control (an antibiotic known
to cause this effect). We conducted the
trial in a major university hospital. An
anesthesiologist took twitch monitor mea-
surements. This machine stimulates nerve
causing muscle fibers to twitch; this allows
a quantitative monitoring of the blockade.
The study confirmed piperacillin caused
neuromuscular blockade and the control
antibiotic showed the same amount of
blockade as had been previously reported
(2). We reported our findings to the FDA.
This led to the following label change for
piperacillin (3): When used in the periop-
erative period, piperacillin has been impli-
cated in the prolongation of the neuro-
muscular blockade of vecuronium. Cau-
tion is indicated when piperacillin is used
perioperatively. In one controlled clini-
cal study, the ureidopenicillins, including
piperacillin, were reported to prolong the
action of vecuronium. Due to their simi-
lar mechanism of action, it is expected that
the neuromuscular blockade produced by
any of the non-depolarizing muscle relax-
ants could be prolonged in the presence of
piperacillin.
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